Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines

Mari,Emanuela; Zicari,Alessandra; Fico,Flavia; Massimi,Isabella; Martina,Lolli; Mardente,Stefania

doi:10.3892/ol.2016.4876

Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines

Authors:
- Emanuela Mari
- Alessandra Zicari
- Flavia Fico
- Isabella Massimi
- Lolli Martina
- Stefania Mardente
View Affiliations

Affiliations: Department of Experimental Medicine, Sapienza University of Rome, I‑00161 Rome, Italy
Published online on: July 18, 2016 https://doi.org/10.3892/ol.2016.4876
Pages: 2133-2138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA (miR/miRNA) are small non-coding RNAs that control gene expression at the post-transcriptional level by targeting mRNAs. Aberrant expression of miRNAs is often observed in different types of cancer. Specific miRNAs function as tumor suppressors or oncogenes and interfere with various aspects of carcinogenesis, including differentiation, proliferation and invasion. Upregulation of miRNAs 221 and 222 has been shown to induce a malignant phenotype in numerous human cancers via inhibition of phosphatase and tensin homolog (PTEN) expression. Neuroblastoma is the most common extracranial solid malignancy in children, which is characterized by cellular heterogeneity that corresponds to different clinical outcomes. The different cellular phenotypes are associated with different gene mutations and miRs that control genetic and epigenetic factors. For this reason miRs are considered a potential therapeutic target in neuroblastoma. The aim of the present study was to investigate the mechanisms by which extracellular high mobility group box 1 (HMGB1) promotes cell growth in neuroblastoma. SK-N-BE(2) and SH-SY5Y neuroblastoma derived cell lines were transfected with the antisense oligonucleotides, anti-miR‑221 and -222, followed by treatment with HMGB1 to investigate the expression of the oncosuppressor PTEN. In this study, it was demonstrated that HMGB1, which is released by damaged cells and tumor cells, upregulates miR‑221/222 oncogenic clusters in the two human neuroblastoma derived cell lines. The results revealed that the oncogenic cluster miRs 221/222 were more highly expressed by the most undifferentiated cell line [SK-N-BE(2)] compared with the the less tumorigenic cell line (SH-SY5Y) and that exogenous HMGB1 increases this expression. In addition, HMGB1 modulates PTEN expression via miR‑221/222, as demonstrated by transiently blocking miR-221/222 with anti-sense oligonucleotides. These results may lead to the development of novel therapeutic strategies for neuroblastoma.

View Figures

View References

1	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
2	Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK and DuBois SG: Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 122:935–945. 2016. View Article : Google Scholar : PubMed/NCBI
3	Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, et al: Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008–3017. 2015. View Article : Google Scholar : PubMed/NCBI
4	Rubie H, De Bernardi B, Gerrard M, et al: Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. (29): 449–455. 2011. View Article : Google Scholar : PubMed/NCBI
5	Wagner LM and Danks MK: New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem. (107): 46–57. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wang L, Che XJ, Wang N, Li J and Zhu MH: Regulatory network analysis of microRNAs and genes in neuroblastoma. Asian Pac J Cancer Prev. 15:7645–7652. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, London WB, Chang CH and Yu AL: MicroRNA signature and expression of dicer and drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 70:7841–7850. 2010. View Article : Google Scholar : PubMed/NCBI
8	Cui C, Yu J, Huang S, Zhu H and Huang Z: Transcriptional regulation of gene expression by micro RNAs endogenous decoys of transcription factors. Cell Physiol Biochem. 33:1698–1714. 2010. View Article : Google Scholar
9	Mei H, Lin ZY and Tong QS: The roles of microRNAs in neuroblastoma. World J Pediatr. 10:10–16. 2010. View Article : Google Scholar
10	Samaraweera L, Grandinetti KB, Huang R, Spengler BA and Ross RA: MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity. BMC Cancer. 14:3092014. View Article : Google Scholar : PubMed/NCBI
11	Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, et al: MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 122:699–704. 2008. View Article : Google Scholar : PubMed/NCBI
12	Thomas SK, Messam CA, Spengler BA, Biedler JL and Ross RA: Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem. 279:27994–27999. 2004. View Article : Google Scholar : PubMed/NCBI
13	Rothermund K, Rogulski K, Fernandes E, Whiting A, Sedivy J, Pu L and Prochownik EV: C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res. 65:2097–2107. 2005. View Article : Google Scholar : PubMed/NCBI
14	Armstrong MB, Mody RJ, Ellis DC, Hill AB, Erichsen DA and Wechsler DS: N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma. Neoplasia. 15:1363–1370. 2013. View Article : Google Scholar : PubMed/NCBI
15	Liu Y and Song L: HMGB1-induced autophagy in Schwann cells promotes neuroblastoma proliferation. Int J Clin Exp Pathol. 8:504–510. 2015.PubMed/NCBI
16	Mardente S, Mari E, Massimi I, Fico F, Faggioni A, Pulcinelli F, Antonaci A and Zicari A: HMGB1-induced cross talk between PTEN and miRs 221/222 in thyroid cancer. Biomed Res Int 2015:: 512027. 2015. View Article : Google Scholar
17	Ayers D, Mestdagh P, Van Maerken T and Vandesompele J: Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J. 13:307–319. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Qiao L, Paul P, Lee S, Qiao J, Wang Y and Chung DH: Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells. Biochem Biophys Res Commun. 435:295–299. 2013. View Article : Google Scholar : PubMed/NCBI
20	Guglielmi L, Cinnella C, Nardella M, Maresca G, Valentini A, Mercanti D, Felsani A and D'Agnano I: MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death Dis. 5:e10812014. View Article : Google Scholar : PubMed/NCBI
21	Li W, Guo F, Wang P, Hong S and Zhang C: miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med. 14:185–195. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mardente S, Mari E, Consorti F, Di Gioia C, Negri R, Etna M, Zicari A and Antonaci A: HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep. 28:2285–2289. 2012.PubMed/NCBI
23	Zhao Z, Ma X, Hsiao THM, Lin G, Kosti A, Yu X, Suresh U, Chen Y, Tomlinson GE, Pertsemlidis A and Du L: A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget. 15:2499–2512. 2014. View Article : Google Scholar
24	Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 1498:99–111. 2000. View Article : Google Scholar : PubMed/NCBI
25	Sajithlal G, Huttunen H, Rauvala H and Munch G: Receptor for advanced glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma cells. J Biol Chem. 277:6888–6897. 2002. View Article : Google Scholar : PubMed/NCBI
26	Chen J, Song M, Yu S, Gao P, Yu Y, Wang H and Huang L: Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol Cell Biochem. 335:137–146. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wang L, Li S and Jungalwala FB: Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J Neuroscience Res. 86:1254–1266. 2010. View Article : Google Scholar